PALO ALTO, Calif., Sept. 15 /PRNewswire/ -- Affymax, Inc. announced today the publication of clinical data from its Phase 1 trial of Hematide(TM) in the September 15 issue of the scientific journal Blood. The study results demonstrated that single doses of Hematide resulted in dose-dependent increases in circulating reticulocytes in normal healthy volunteers and in a clinically and statistically significant increase in red blood cells and hemoglobin from baseline, which was sustained for at least one month. Hematide, the Company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is currently in Phase 2 trials for the treatment of anemia associated with chronic kidney disease and in anemic cancer patients undergoing chemotherapy.
